These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 38610074)
1. EGFR degraders in non-small-cell lung cancer: Breakthrough and unresolved issue. Shen J; Chen L; Liu J; Li A; Zheng L; Chen S; Li Y Chem Biol Drug Des; 2024 Apr; 103(4):e14517. PubMed ID: 38610074 [TBL] [Abstract][Full Text] [Related]
2. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
3. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Lee EJ; Oh SY; Lee YW; Kim JY; Kim MJ; Kim TH; Lee JB; Hong MH; Lim SM; Baum A; Woelflingseder L; Engelhardt H; Petronczki M; Solca F; Yun MR; Cho BC Clin Cancer Res; 2024 Apr; 30(8):1582-1594. PubMed ID: 38330145 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib. Obst-Sander U; Ricci A; Kuhn B; Friess T; Koldewey P; Kuglstatter A; Hewings D; Goergler A; Steiner S; Rueher D; Imhoff MP; Raschetti N; Marty HP; Dietzig A; Rynn C; Ehler A; Burger D; Kornacker M; Schaffland JP; Herting F; Pao W; Bischoff JR; Martoglio B; Alice Nagel Y; Jaeschke G J Med Chem; 2022 Oct; 65(19):13052-13073. PubMed ID: 36178776 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer. Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625 [TBL] [Abstract][Full Text] [Related]
7. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. Shaikh M; Shinde Y; Pawara R; Noolvi M; Surana S; Ahmad I; Patel H J Med Chem; 2022 Jan; 65(2):1008-1046. PubMed ID: 34323489 [TBL] [Abstract][Full Text] [Related]
8. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations. Du Y; Chen Y; Wang Y; Chen J; Lu X; Zhang L; Li Y; Wang Z; Ye G; Zhang G Mol Cancer Ther; 2022 Jul; 21(7):1060-1066. PubMed ID: 35499406 [TBL] [Abstract][Full Text] [Related]
9. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer. Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102 [TBL] [Abstract][Full Text] [Related]
10. Acquired Resistance to Osimertinib in Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940 [TBL] [Abstract][Full Text] [Related]
11. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341 [TBL] [Abstract][Full Text] [Related]
12. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468 [TBL] [Abstract][Full Text] [Related]
13. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S. Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819 [TBL] [Abstract][Full Text] [Related]
14. Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib. Rotow JK; Lee JK; Madison RW; Oxnard GR; Jänne PA; Schrock AB J Thorac Oncol; 2024 Feb; 19(2):227-239. PubMed ID: 37806383 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709 [TBL] [Abstract][Full Text] [Related]
16. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive Takeda M; Nakagawa K Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609789 [TBL] [Abstract][Full Text] [Related]
17. Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies. Leonetti A; Verzè M; Minari R; Perrone F; Gnetti L; Bordi P; Pluchino M; Nizzoli R; Azzoni C; Bottarelli L; Lagrasta CAM; Mazzaschi G; Buti S; Gasparro D; Cosenza A; Ferri L; Majori M; De Filippo M; Ampollini L; La Monica S; Alfieri R; Silini EM; Tiseo M Br J Cancer; 2024 Jan; 130(1):135-142. PubMed ID: 37938348 [TBL] [Abstract][Full Text] [Related]
18. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670 [TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083 [TBL] [Abstract][Full Text] [Related]
20. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. Wang S; Tsui ST; Liu C; Song Y; Liu D J Hematol Oncol; 2016 Jul; 9(1):59. PubMed ID: 27448564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]